

REMARKS

Claims 47 and 49 have been amended, in particular, to reflect a chemical name for the compound identified in the original claims and specification as R0 15-1788. As indicated in the specification on page 41, line 34, R0 15-1788 is also known as Flumazenil. This compound can be named as 8-Fluoro-5,6-dihydro-5-methyl-6-oxo-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylic acid ethyl ester. See the Merck Index, 13<sup>th</sup> Edition, monograph no. 4161 at page 731 (Merck & Co, Whitehouse Station, NJ).

The Examiner requested, in a telephone call to the undersigned on September 29, 2003, that claim 49 be clarified with respect to the identify of R0 15-1788. Applicants believe the recitation of R0 15-1788 did not render the original claims unclear as those skilled in the art recognize R0 15-1788 as Flumazenil. There is no confusion in the art as to the identity of R0 15-1788. Thus, Applicants respectfully submit that no amendment to the claims is necessary. Nevertheless, to expedite allowance of the case, Applicants have amended claims 47 and 49 to reflect a suitable chemical name for that compound. The amendments merely identify R0 15-1788 in a different manner. Accordingly, no new matter is added by this amendment.

Allowance of the claims and passage of the case to issue are respectfully solicited. Should the Examiner believe a

discussion of this matter would be helpful, the Examiner is invited to telephone the undersigned at (312) 913-0001.

Respectfully submitted,



Steven J. Barussi  
Reg. No. 32,784

Date: October 7, 2003

McDonnell Boehnen Hulbert &  
Berghoff  
300 South Wacker Drive  
Chicago, Illinois 60606  
(312) 913-0001